Grifols (GIKLY) Total Non-Current Liabilities (2010 - 2025)
Grifols (GIKLY) reported Total Non-Current Liabilities of $11.7 billion for Q4 2025, up 3.27% on a YoY basis from $11.4 billion in Q4 2024, and up 3.27% quarter-over-quarter from $11.4 billion in Q4 2024.
Grifols (GIKLY) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
Grifols has reported Total Non-Current Liabilities for 16 years, with the latest figure at $11.7 billion in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.27% year-over-year to $11.7 billion; the trailing twelve-month figure through Dec 2025 stood at $11.7 billion (up 3.27% YoY), and the FY2025 full-year result was $11.7 billion, up 20873.57% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $11.7 billion, up from $11.4 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $12.0 billion in Q4 2023, with the low at $9.7 billion in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $11.2 billion across 5 years, with a median of $11.5 billion in 2022.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 18.68% — and 2024, when it declined 5.22%.
- Grifols' Total Non-Current Liabilities stood at $9.7 billion in 2021, then gained by 18.68% to $11.5 billion in 2022, then advanced by 4.7% to $12.0 billion in 2023, then slipped by 5.22% to $11.4 billion in 2024, then advanced by 3.27% to $11.7 billion in 2025.
- The last three Total Non-Current Liabilities figures came in at $11.7 billion (Q4 2025), $11.4 billion (Q4 2024), and $12.0 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Grifols | - | - | - | 11.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.75 Bn |
| Dec 31, 2024 | 11.37 Bn |
| Dec 31, 2023 | 12.00 Bn |
| Dec 31, 2022 | 11.46 Bn |
| Dec 31, 2021 | 9.66 Bn |
| Dec 31, 2020 | 8.61 Bn |
| Sep 30, 2020 | 8.52 Bn |
| Mar 31, 2020 | 8.12 Bn |
| Dec 31, 2019 | 8.11 Bn |
| Sep 30, 2019 | 8.18 Bn |
| Mar 31, 2019 | 550,128.37 |
| Dec 31, 2018 | 7.45 Bn |
| Sep 30, 2018 | 7.61 Bn |
| Jun 30, 2018 | 7.69 Bn |
| Mar 31, 2018 | 8.96 Bn |
| Dec 31, 2017 | 7.43 Bn |
| Jun 30, 2017 | 7.29 Bn |
| Mar 31, 2017 | -289,790.68 |
| Dec 31, 2016 | 5.75 Bn |
| Sep 30, 2016 | 5.70 Bn |